



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/195, 31/47, 33/30, 31/325, 31/42, 31/13, 31/44		A2	(11) International Publication Number: WO 97/09976 (43) International Publication Date: 20 March 1997 (20.03.97)
(21) International Application Number: PCT/IB96/00981 (22) International Filing Date: 23 August 1996 (23.08.96)		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 60/003,134 1 September 1995 (01.09.95) US 60/007,356 20 November 1995 (20.11.95) US		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(71) Applicant: WASHINGTON UNIVERSITY (US/US); One Brookings Drive, Campus Box 8013, St. Louis, MO 63130 (US).			
(72) Inventors: CHOI, Dennis, Wonkyu; 7400 Forsyth Boulevard, St. Louis, MO 63105 (US). KOH, Jae-young; 8148 Flintstone Trail, St. Louis, MO 63123 (US).			
(74) Agent: POKRAS, Bruce, A.; 340 Kingsland Street, Nutley, NJ 07110-1199 (US).			
(54) Title: METHOD OF REDUCING NEUROTOXIC INJURY WITH ZINC CHELATORS			
(57) Abstract The invention relates to the use of pharmaceutically acceptable zinc chelating compounds for the manufacture of medicaments for the treatment of neurotoxic injury.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Method of reducing neurotoxic injury with zinc chelators

The invention relates to the use of zinc chelating compounds in the treatment of neurotoxic injury.

It has been discovered that zinc chelating compounds protect

- 5 hippocampal neurons from the neurotoxic effects of Zn^{2+} released during neurotoxic events, such as ischemia as a result of stroke or cardiac arrest. Thus, the present invention comprises a method of treating neurotoxic injury in a patient suffering said injury, comprising administering to said patient a zinc chelating compound in an amount sufficient to treat said neurotoxic injury.

The administration of the composition comprising the zinc chelating compound is carried out by injection or infusion of the composition into the patients cerebrospinal fluid.

Chelatable Zn^{2+} is present in large quantities in presynaptic vesicles of

- 15 central excitatory neurons (Danscher et al., 1985; Frederickson et al., 1983), and released with synaptic activity or membrane depolarization (Assaf and Chung, 1984; Howell et al., 1984; Charton et al., 1985). Although the precise role of released synaptic zinc is not known, it blocks NMDA receptor-mediated current (Westbrook and Mayer, 1987; Peters et al., 1987; Christine and Choi, 1990) and GABA receptor-mediated current (Westbrook and Mayer, 1987), as well as voltage-dependent calcium channels (Winegar and Lansman, 1990). In addition, exposure to excessive extracellular Zn^{2+} is neurotoxic to cortical neurons (Choi et al., 1988), possibly mediated by Zn^{2+} influx in part mediated by ionotropic glutamate receptors and voltage-gated
- 20 calcium channels (Weiss et al., 1993; Koh and Choi, 1994). Recently, it has been shown that zinc translocates into degenerating hippocampal hilar neurons after transient ischemia (Tonder et al., 1990) or kainate-induced seizures (Frederickson et al., 1989).

Treating neurotoxic injury within the meaning of the present invention

- 30 means reducing the extent of damage to central neurons surrounding a central neuron which has released Zn^{2+} due to its having been damaged by a

neurotoxic event. Neurotoxic events include acute neurological insults such as hypoxia/ischemia, such as occurs during stroke, cardiac arrest, hypoglycemia, epilepsy or trauma. Neurotoxic events may also be chronic neuronal damage caused by neurodegenerative disorders such as

5 Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and the neurodegenerative effects of AIDS. Thus, the present invention also comprises a method of treating diseases, such as those described above, in which said neurotoxic injury occurs.

The zinc chelating compounds useful in accordance with the invention
10 are not critical. Any conventional compound which is capable of chelating Zn^{2+} and which is pharmaceutically acceptable for injection into cerebral spinal fluid may be used in accordance with the invention.

While ethylenediaminetetraacetic acid (EDTA) is traditionally used as an organic chelating agent for Ca^{2+} , it has affinity for other divalent metal
15 ions, and specifically binds Zn^{2+} with much higher affinity than Ca^{2+} (log stability constant at pH 7, 13.1 for Zn^{2+} versus 7.3 for Ca^{2+}). An equimolar combination for Ca^{2+} and EDTA will act as a chelating agent for Zn^{2+} without chelating local Ca^{2+} (Dansher et al., 1975). Thus, the preferred zinc chelating compound for use in accordance with the invention is disodium-
20 calcium EDTA ("CaEDTA"), especially the form of CaEDTA known as edetate calcium disodium injection, USP (e.g., Calcium Disodium Versenate, 3M Pharmaceuticals, St. Paul, Minnesota).

Another preferred zinc chelating compound useful in accordance with the invention is 3-mercaptop-D-valine (penicillamine), which is a chelating agent usually applied to the treatment of Wilson's disease where it removes
25 excess copper.

Other zinc chelating compounds useful in accordance with the invention are:

bis(diethylthiocarbamoyl) disulfide (Disulfiram or Antabuse),
30 (ethylenedioxy)diethylenedinitrilotetraacetic acid (EGTA),
N,N,N',N'-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN),
N-(6-methoxy-8-quinolyl)-p-toluenesulfonamide (TSQ),
8-hydroxy quinoline (Oxyne),
35 8-hydroxy quinoline-5-sulphonic acid (Sulphoxine),
diethyl dithiocarbamate (DEDTC),

1,10-phenanthroline,
dipicolinate,
N-acetyl cystein,
diphenylthiocarbazone (Dithizone),
5 1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-5'-methylphenoxy)ethane-N,N,N',N'-tetraacetic acid (Fura-2), and
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA).

The zinc chelating compound used in accordance with the present invention may be administered to the cerebrospinal fluid by any conventional means. The preferred method of administration is by injection or chronic pump infusion into the lateral ventricles of the patient's brain or into the lumbar sac of the patient.

The zinc chelating compound is preferably administered as a composition containing the zinc chelating compound and a pharmaceutically acceptable carrier compatible with the compound. In preparing such a composition, any conventional pharmaceutically acceptable carrier may be utilized. Typical carriers for administration by injection would be sterile aqueous/buffered solutions, preferably water for injection or unbuffered or buffered physiological saline. The zinc chelating compound is preferably present in the carrier at a concentration of 1 mM - 300 mM, especially from 50 mM - 200 mM.

In carrying out the method of the invention, the zinc chelating compound is administered to adults daily in an amount from about 0.1 mg/kg to about 100 mg/kg daily, in single or divided doses, or continuously through chronic pump infusion. The preferred dosage will vary depending upon the indication for which the method of the invention is being used to treat. For treatment of patients who have suffered an acute neurotoxic insult, as a result of, e.g., stroke or cardiac arrest, the administration of a dosage from about 5 mg/kg to about 50 mg/kg daily, carried out for from 1 to 7 days, is preferred. Administration may be carried out by injection or by infusion utilizing a chronic infusion pump. For treatment of chronic neurotoxic conditions in patients, e.g., Alzheimer's disease, a dosage of from about 1 mg/kg to about 10 mg/kg daily is preferred, carried out for months to years, preferably utilizing a chronic infusion pump.

35 Thus, the present invention also comprises a method of treating neurotoxic injury in a patient suffering said injury by administering to said

patient a composition comprising a zinc chelating compound and carrier, wherein both the compound and the carrier are pharmaceutically acceptable for injection. The preferred zinc chelating compounds are CaEDTA and 3-mercaptop-D-valine, with CaEDTA being especially preferred. The zinc

- 5 chelating compound is preferably administered in an amount from about 0.1 mg/kg to about 100 mg/kg daily, especially in an amount from about 5 mg/kg to about 50 mg/kg daily for the treatment of acute neurotoxic conditions and in an amount from about 1 mg/kg to about 10 mg/kg daily for chronic neurotoxic conditions. The preferred method of administration is the
- 10 injection or infusion of the pharmaceutical composition comprising the zinc chelating compound and the carrier into the cerebrospinal fluid (e.g., the lateral ventricles or lumbar sac) of the patient. The preferred duration of treatment is from 1 to 7 days for acute neurotoxic conditions, and for months to years for chronic neurotoxic conditions.

- 15 The present invention preferably comprises a method of treating stroke in a patient suffering said stroke by administering to said patient a composition comprising a zinc chelating compound and a carrier, wherein both the compound and the carrier are pharmaceutically acceptable for injection. The preferred zinc chelating compounds are CaEDTA and 3-mercaptop-D-valine, with CaEDTA being especially preferred. The zinc chelating compound is preferably administered in an amount from about 0.1 mg/kg to about 100 mg/kg daily, especially in an amount from about 5 mg/kg to about 50 mg/kg daily for the treatment of stroke. The preferred method of administration is the injection or infusion, especially injection, of the
- 20 pharmaceutical composition comprising the zinc chelating compound and the carrier into the cerebrospinal fluid (e.g., the lateral ventricles or lumbar sac) of the patient. The preferred duration of treatment is from 1 to 7 days.
- 25

- 30 Experiments were conducted which determined that a zinc chelating compound, CaEDTA, exhibited neuroprotective effects in cell culture and animal models of brain hypoxic-ischemic injury, such as might occur consequent to cardiac arrest or stroke. Several observations were made:

- 35 1) In mouse cortical culture, CaEDTA selectively blocks Zn²⁺-induced neuronal degeneration, but not the Ca²⁺-overload neurotoxicity induced by glutamate agonists.
- 2) In a rat model of transient forebrain ischemia (bilateral carotid occlusion combined with hypotension), intraventricular injections of

CaEDTA, 30 minutes prior to the beginning of ischemia, reduced the ischemia-induced translocation of Zn^{2+} from presynaptic terminals throughout the brain to degenerating postsynaptic neurons. This CaEDTA treatment also markedly reduced the death of hippocampal hilar and CA1 pyramidal neurons.

Example 1

Use of disodium-calcium-EDTA (CaEDTA) in a rat model of transient global ischemia.

5 μ l of 100 mM CaEDTA in saline, or saline alone, was injected into the 10 lateral ventricles of Long Evans rats, 30 minutes prior to the inducement of 10 minutes of global ischemia. Ischemia was delivered by ligation of both common carotid arteries combined with hypotension after anesthesia (Smith et al., 1984).

Hippocampal sections from the treated and untreated rats were stained 15 with the zinc-sensitive dye, TSQ (Frederickson et al., 1987). The examination of these sections showed that in the untreated rats zinc translocated from presynaptic inputs to degenerating hilar neuronal cell bodies between 3-24 hours after the ischemia. In the treated rats, CaEDTA blocked not only this zinc translocation, but also prevented subsequent hilar neuronal 20 degeneration as assessed 3 days later.

TSQ staining also revealed the delayed appearance of zinc in CA1 pyramidal neuronal cell bodies of untreated rats 24-72 hours post ischemia. The CaEDTA treatment prior to the induced ischemia attenuated both the 25 appearance of zinc in CA1 pyramidal neurons, and CA1 neuronal degeneration.

Control intraventricular injections of zinc EDTA, which is not a zinc chelating compound, did not alter the zinc translocation or hippocampal neuronal death following the ischemia in treated rats.

These results demonstrate that extracellular Zn^{2+} chelating 30 compounds protect brain cells against neurotoxic injury which can be the result of ischemia or other neurodegenerative conditions associated with Zn^{2+} release.

Claims

1. The use of pharmaceutically acceptable zinc chelating compounds for the manufacture of medicaments for the treatment of neurotoxic injury.
2. The use of zinc chelating compounds according to claim 1, wherein 5 the therapeutic indications include neurological insults such as ischemia as a result of stroke, cardiac arrest, hypoglycemia, epilepsy or trauma, neurodegenerative disorders such as Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and the neurodegenerative effects of AIDS.
- 10 3. The use of zinc chelating compounds according to claims 1 and 2, wherein the zinc chelating compounds are selected from the group consisting of disodium-calcium-ethylenediaminetetraacetic acid, 3-mercaptop-D-valine,
- 15 (ethylenedioxy)diethylenedinitrilotetraacetic acid (EGTA), N,N,N',N'-tetrakis(2-pyridylmethyl)-ethylenediamine, N-(6-methoxy-8-quinolyl)-p-toluenesulfonamide, 8-hydroxy quinoline, 8-hydroxy quinoline-5-sulphonic acid,
- 20 diethyl-dithiocarbamate, bis(diethylthiocarbamoyl)-disulfide, 1,10-phenanthroline, dipicolinate, N-acetyl cystein,
- 25 diphenylthiocarbazone, 1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-5'-methylphenoxy)ethane-N,N,N',N'-tetraacetic acid and 1,2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid.
- 30 4. A medicament containing one or more zinc chelating compounds as defined in claim 3 and a pharmaceutically acceptable inert carrier for the treatment of neurotoxic injury which include neurological insults such as ischemia as a result of stroke, cardiac arrest, hypoglycemia, epilepsy or trauma, neurodegenerative disorders such as Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and the 35 neurodegenerative effects of AIDS.

5. A method of treating neurotoxic injury in a patient suffering said injury by injecting or infusing into the cerebrospinal fluid of said patient a composition comprising a pharmaceutically acceptable zinc chelating compound as defined in claim 3 and a pharmaceutically acceptable carrier 5 wherein said zinc chelating compound is present in said composition in an amount sufficient to treat said neurotoxic injury.
6. The method according to claim 5, wherein the zinc chelating compound is administered at a dosage in the range from about 0,1 mg/kg to about 100 mg/kg daily.

10

THIS PAGE BLANK (USPTO)